Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:05:43.348Z.
Calculation as of: 2026-10-06T12:05:43.348Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
EV/EBITDA Ratio
N/A
TTM Avg
56.92x
3Y Avg
58.14x
5Y Avg
58.14x
Market Cap
$1.12B
EV/EBITDA Ratio
8.82x
TTM Avg
7.81x
3Y Avg
9.53x
5Y Avg
11.97x
Market Cap
$1.16B
EV/EBITDA Ratio
8.32x
TTM Avg
7.52x
3Y Avg
19.65x
5Y Avg
29.89x
Market Cap
$1.20B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.21B
EV/EBITDA Ratio
27.60x
TTM Avg
20.27x
3Y Avg
20.27x
5Y Avg
20.27x
Market Cap
$1.05B
EV/EBITDA Ratio
12.93x
TTM Avg
29.00x
3Y Avg
192.84x
5Y Avg
192.84x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A | 56.92x | 58.14x | 58.14x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 8.82x | 7.81x | 9.53x | 11.97x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 8.32x | 7.52x | 19.65x | 29.89x |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.21B | 27.60x | 20.27x | 20.27x | 20.27x |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 12.93x | 29.00x | 192.84x | 192.84x |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 2.11x | 2.11x | 2.11x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
